Life sciences supply & technology

503A & RUO peptide fulfilment, direct sourcing, and healthcare technology for clinics

Novarde Life Sciences connects licensed clinics and physicians to the right supply channel— and backs it with brokerage software and regulated consulting.

Clinic & physician supply

Sourcing and peptide fulfilment pathways

Novarde connects licensed operators to the right supply channel—direct material sourcing, API-driven 503A compounding fulfilment, and wholesale RUO peptides for research use.

Channel

Direct sourcing

Source APIs, intermediates, and specialty materials through vetted manufacturer and distributor relationships—with documentation, logistics coordination, and partner matching for clinics and practice groups.

Learn about sourcing

Clinical fulfilment

API-driven 503A peptides

Nationwide fulfilment for clinics and physicians in all 50 U.S. states through licensed 503A compounding pathways. API-connected ordering, lot traceability, and coordinated handoff so practices can move from request to dispensed preparation with fewer manual steps.

503A fulfilment details

RUO products are for laboratory research use only and are not intended for human consumption, diagnostic, or therapeutic use. 503A fulfilment is available only through appropriately licensed compounding pharmacies and authorized clinic / physician channels. Compounded preparations are not FDA-approved drugs.

Platform

Software for brokerage and operations

Purpose-built applications across trading-partner CRM, specialty capital, and clinical intelligence—each on a dedicated secure domain.

Available crm.novarde.com

Luxaro BrokerageOS

Luxaro Healthcare Brokers

Pharma CRM for buyers, suppliers, pipeline, quotes, commissions, and compliance documentation across regulated trading partners.

Create a profile
Coming soon —

RegenCapitalOS

Capital operations

Workflow software for regenerative and specialty capital teams. Access will open here when the release is ready.

Not available yet
Coming soon —

AisendraAI

Healthcare intelligence

AI systems for healthcare decision support and operational automation. Product surface publishing soon.

Not available yet

Consulting

Facility, compliance, and formulation support

Alongside supply and software, we help operators stand up regulated capacity, stay inspection-ready, and move formulation work from concept to manufacture-ready pathways.

Facility consulting

Source and facilitate laboratory and manufacturing buildouts—site selection, partner introductions, equipment pathways, and project coordination from planning through commissioning.

Compliance consulting

Practical compliance recommendations for pharmacies, manufacturers, distributors, and trading partners—documentation structure, licensing readiness, and inspection-minded operating practices.

Formulation consulting

Facilitate R&D and formulation work with the right development partners—compounding strategies, peptide and specialty pathways, scale-up planning, and handoff into manufacturing capacity.

Talk with our team

FAQ

Common questions about Novarde

Clear answers help clinics, physicians, and research buyers—and help search engines and AI assistants cite the right channel.

What does Novarde Life Sciences do?

Novarde provides direct pharmaceutical sourcing, API-driven 503A peptide fulfilment for clinics and physicians through licensed compounding pathways, wholesale RUO peptides for research, Luxaro BrokerageOS software, and facility, compliance, and formulation consulting.

Who is 503A peptide fulfilment for?

Authorized clinics, physicians, and licensed healthcare practices nationwide— available in all 50 U.S. states—that need patient-specific fulfilment through licensed 503A compounding pharmacy pathways. Read the 503A overview.

What are RUO peptides?

Research use only. Wholesale RUO peptides are for laboratory research and are not intended for human consumption, diagnosis, or therapy. RUO overview · Research intake.

Are compounded peptides FDA-approved?

No. Compounded preparations are not FDA-approved drugs. Novarde does not market compounded peptides as FDA-approved products or make disease-treatment outcome claims.